Real‐world outcomes of triplet therapy with gilteritinib, azacitidine and venetoclax in FMS‐like tyrosine kinase 3 ( FLT3 )‐mutated relapsed/refractory acute myeloid leukaemia: A UK single‐centre experience
British Journal of Haematology · 2026
DOI: 10.1111/bjh.70676 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Haematology, 2026. Verfasst von Wei Yee Chan und 19 weiteren Autor:innen. Beteiligte Einrichtung: University College London Hospitals, NHS Foundation Trust, London, UK. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, fms-Like Tyrosine Kinase 3, Antineoplastic Combined Chemotherapy Protocols, Mutation. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
In FMS-like tyrosine kinase 3 (FLT3)-mutated relapsed/refractory acute myeloid leukaemia, gilteritinib, azacitidine and venetoclax is an effective salvage option with an ORR of 100% (mCRc [MLFS + CRc] 93%). Sixty-two per cent of patients treated with intention-to-transplant proceeded to allogeneic haematopoietic stem cell transplant, of whom 50% remain in long-term remission (median follow-up 43 months).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University College London Hospitals, NHS Foundation Trust, London, UK.
- University College London, London, UK.
- GOS Institute of Child Health, UCL, London, UK.
ORCID-Profile: Wei Yee Chan, Hannah Al-Yousuf, Sarah Leong, Richard Burt, Ke Xu, Samah Alimam, Kavita Raj, Anish Tailor, Elspeth M Payne
Zitieren
APA
Chan, W. Y., Al-Yousuf, H., Lam, H. P. J., Leong, S., Zheng, J., Burt, R., Wilson, A. J., Xu, K., Stringaris, K., Alimam, S., Raj, K., Gupta, R., Kottaridis, P., Tailor, A., Burgoyne, R., Mansour, M. R., Khwaja, A., Sellar, R., Payne, E. M., & O'Nions, J. (2026). Real‐world outcomes of triplet therapy with gilteritinib, azacitidine and venetoclax in FMS‐like tyrosine kinase 3 ( FLT3 )‐mutated relapsed/refractory acute myeloid leukaemia: A UK single‐centre experience. British Journal of Haematology. https://doi.org/10.1111/bjh.70676
Vancouver
Chan WY, Al-Yousuf H, Lam HPJ, Leong S, Zheng J, Burt R, et al. Real‐world outcomes of triplet therapy with gilteritinib, azacitidine and venetoclax in FMS‐like tyrosine kinase 3 ( FLT3 )‐mutated relapsed/refractory acute myeloid leukaemia: A UK single‐centre experience. British Journal of Haematology. 2026. doi:10.1111/bjh.70676
BibTeX
@article{Chan2026,
author = {Chan, Wei Yee and Al-Yousuf, Hannah and Lam, Ho Pui Jeff and Leong, Sarah and Zheng, Jiexin and Burt, Richard and Wilson, Andrew J and Xu, Ke and Stringaris, Kate and Alimam, Samah and Raj, Kavita and Gupta, Rajeev and Kottaridis, Panagiotis and Tailor, Anish and Burgoyne, Rebecca and Mansour, Marc R and Khwaja, Asim and Sellar, Rob and Payne, Elspeth M and O'Nions, Jenny},
title = {Real‐world outcomes of triplet therapy with gilteritinib, azacitidine and venetoclax in FMS‐like tyrosine kinase 3 ( FLT3 )‐mutated relapsed/refractory acute myeloid leukaemia: A UK single‐centre experience},
journal = {British Journal of Haematology},
year = {2026},
doi = {10.1111/bjh.70676}
}
EUVIMED